Last quarter (Q4 2023), Achieve Life Sciences's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Achieve Life Sciences's net income was $-5.48M. See Achieve Life Sciences’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	$ -33.09M	-	-
Gross Profit	-	-	-	$ 33.09M	-	-
Operating Expense	$ 27.25M	$ 27.25M	$ 40.80M	$ 33.09M	$ 14.75M	$ 16.53M
Operating Income	$ -27.25M	$ -27.25M	$ -40.80M	$ -33.09M	$ -14.75M	$ -16.53M
Net Non Operating Interest Income Expense	$ -2.03M	$ -2.03M	$ -1.59M	$ 17.00K	$ 69.00K	$ 170.00K
Other Income Expense	$ 537.00K	$ 537.00K	$ -40.00K	$ 75.00K	$ -49.00K	$ -37.00K
Pretax Income	$ -29.82M	$ -29.82M	$ -42.35M	$ -33.15M	$ -14.73M	$ -16.39M
Tax Provision	$ -169.00K	$ -169.00K	$ -51.00K	$ -17.00K	-	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -29.82M	$ -29.82M	$ -42.35M	$ -33.15M	$ -14.73M	$ -16.39M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 27.25M	$ 27.25M	$ 40.80M	-	$ 14.75M	$ 16.53M
Net Income From Continuing And Discontinued Operation	$ -29.82M	$ -29.82M	$ -42.35M	$ -33.15M	$ -14.73M	$ -16.39M
Normalized Income	$ -17.24M	$ -29.46M	-	-	$ -14.73M	$ -16.39M
Interest Expense	-	-	-	-	-	-
EBIT	$ -26.96M	$ -26.96M	$ -40.56M	$ -33.15M	$ -14.75M	$ -16.53M
EBITDA	$ -26.73M	$ -26.73M	$ -40.33M	$ -32.90M	$ -14.49M	$ -16.27M

Currency in USD

Achieve Life Sciences Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing